All In Biotech

Drug Trial Radar · NCT03306264

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

227

Actual

Start

Feb 15, 2018

Primary completion

Sep 10, 2021

Study completion May 25, 2023

Sponsor

Lead sponsor
Astex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.

Conditions

  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Acute Myeloid Leukemia

Interventions

  • ASTX727Drug

    ASTX727 oral tablet

  • DacogenDrug

    Decitabine 20 mg/m\^2 one-hour IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV DecitabineTime frame: ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)

Locations

84 sites in 10 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Arizona Clinical Research Center

    Tucson, Arizona

  • Compassionate Cancer Care Research Group

    Fountain Valley, California

  • University of Southern California

    Los Angeles, California

  • Yale

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Boca Raton Clinical Research

    Boca Raton, Florida

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Mount Sinai

    Miami Beach, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Quincy Medical Group

    Quincy, Illinois

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Johns Hopkins

    Baltimore, Maryland

  • Regional Cancer Care Associates

    Bethesda, Maryland

  • Michigan Center of Medical Research

    Farmington Hills, Michigan

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Hackensack

    Hackensack, New Jersey

  • Roswell Park

    Buffalo, New York

  • Monter Cancer Center

    Lake Success, New York

  • Weill Cornell Medicine

    New York, New York

  • Montefiore

    The Bronx, New York

  • Gabrail Cancer Center

    Canton, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health & Sciences University

    Portland, Oregon

  • West Penn Allegheny Cancer Institute

    Pittsburgh, Pennsylvania

  • University of Pittsburgh Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Charleston Hematology Oncology Associates

    Charleston, South Carolina

  • Vanderbilt

    Nashville, Tennessee

  • Baylor Scott & White University Medical Center

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Cancer Center

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Uniklinikum Salzburg

    Salzburg, Austria

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.